Topical corticosteroid therapy and pituitary-adrenal function.
Systemic absorption has been reported after the use of corticosteroid eye drops. Prolonged use could result in adrenocortical insufficiency and an associated adrenal crisis under stressful situations. For that reason, we studied the hypothalamic-pituitary-adrenal axis of patients receiving corticosteroid eye drope. Fifteen patients were given 0.1% dexamethasone sodium phosphate eye drops, one drop (approximately 1/30 ml) to each eye four times a day for six weeks. This dosage resulted in partial adrenal suppression, manifested by reduced levels of plasma cortisol. However, in each case, the hypothalamic-pituitary-adrenal axis, as evaluated with the use of the oral metyrapone tartrate test, was intact.
D000287:Administration, Topical; D003350:Cortodoxone / Q000097:blood; D003907:Dexamethasone / Q000494:pharmacology* / Q000627:therapeutic use; D005901:Glaucoma / Q000097:blood / Q000188:drug therapy; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007031:Hypothalamus / Q000187:drug effects; D007429:Intraocular Pressure / Q000187:drug effects; D008797:Metyrapone / Q000494:pharmacology; D009883:Ophthalmic Solutions; D010912:Pituitary-Adrenal Function Tests; D010913:Pituitary-Adrenal System / Q000187:drug effects*
D009883:Ophthalmic Solutions; D003907:Dexamethasone; D003350:Cortodoxone; D006854:Hydrocortisone; D008797:Metyrapone